BSO LLC, Lakewood, CO
Is BSO LLC registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names BSO LLC in Lakewood, CO, first registered Nov 24, 2015 and most recently registered Oct 21, 2026.
Does BSO LLC hold a Colorado pharmacy license?
No license with this exact name and city was found in the Colorado State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The California State Board of Pharmacy also lists nonresident license NSF 127 for Bso Llc Dba Belmar Select Outsourcing, Lakewood, CO, status Active, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0010082 for BSO LLC (dba Belmar Select Outsourcing), LAKEWOOD, CO, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301011574 for Belmar Select Outsourcing, Lakewood, CO, status Active, as of Nov 10, 2026.
Has BSO LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Jan 10, 2019) and 2 FMD-145 letters (Jun 22, 2020 and Sep 15, 2021) for BSO LLC. State board actions: no Colorado State Board of Pharmacy action under this exact name and city was found in the board’s license dataset (actions dated Oct 11, 1985 to Oct 30, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- BSO LLC; Belmar Select Outsourcing
- Location
- Lakewood, CO
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as BSO LLC
- Form 483s on FDA’s actions page
- 4
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jul 16, 2025
- FDA Data Dashboard inspections
- 5 inspections: 2 OAI, 3 VAI; 4 published Form 483s
- Form 483 text on this page
- 4 Form 483s, 20 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as BSO LLC (dba Belmar Select Outsourcing), a 503B facility, with 7 dated actions.
| Document | |||
|---|---|---|---|
| Jul 16, 2025 | Amended Form 483 | Amended 483 Issued 07/16/2025 | fda.gov |
| Jul 3, 2024 | Form 483 | 483 Issued 07/03/2024 | FDA copy (archived) |
| Sep 15, 2021 | FMD-145 letter | FMD-145 Letter Issued 09/15/2021 | Not linked by FDA |
| Mar 11, 2021 | Form 483 | 483 Issued 03/11/2021 | FDA copy (archived) |
| Jun 22, 2020 | FMD-145 letter | FMD-145 Letter Issued 6/22/2020 | FDA copy (archived) |
| Sep 20, 2019 | Form 483 | 483 Issued 09/20/2019 | FDA copy (archived) |
| Jan 10, 2019 | Untitled letter | Untitled Letter Issued 01/10/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists BSO LLC, Lakewood, CO (FEI number 3011976853), matched to this page by exact name, city and state. It lists 5 inspections: 2 OAI, 3 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 16, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011976853 | 1275884 |
| Jul 3, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011976853 | 1243627 |
| Mar 11, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011976853 | 1136610 |
| Sep 20, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011976853 | 1102385 |
| Sep 2, 2016 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011976853 | 988473 |
Form 483s FDA has published for this site
- Jul 16, 2025: Form 483 to BSO LLC, published Aug 14, 2025. fda.gov
- Jul 3, 2024: Form 483 to BSO LLC, published Oct 2, 2024. fda.gov
- Mar 11, 2021: Form 483 to BSO LLC, published Jun 8, 2021. fda.gov
- Sep 20, 2019: Form 483 to BSO LLC, published Nov 12, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 20 numbered observations in all, across 4 inspections ending Sep 20, 2019 to Jul 16, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 7, 2025 to Jul 16, 2025: 9 observations
- Firm on the cover
- BSO LLC, 12860 W Cedar Dr Ste 211, Lakewood, CO 80228-1971
- FEI number
- 3011976853
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
Specifically,
a. Lack of Potency Data at Maximum Sterilizing Dose Range: Under RAM 24008, dated 08/14/2024, your firm changed the container-closure system for all doses less than 87.5 of Anastrozole, Estradiol, Testosterone, and Testosterone with Cholesterol pellets from <Redacted B4> Amber Vials to <Redacted B4> Clear Vials. You performed a <Redacted B4> (BSO04 dated 05/06/2024) showing that the sterilizing dose increased from <Redacted B4> to <Redacted B4>. However, your firm did not assess the impact of this sterilization range on product quality in the revised container-closure system. Specifically, you were unable to provide pre-and post-sterilization potency data for Anastrozole and Estradiol products packaged in clear vials. Instead, in BSO.ST.034.1, Potency/Sterilization Study Results (signed 11/14/2024), your firm used products packaged in amber glass vials, which does not reflect the current distributed configuration. ...
Observation 2
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
Specifically,
The <Redacted B4> used to train and evaluate personnel performing the visual inspection of liquid injectable products is incomplete. Review of Form 190-02, Liquid Injectables <Redacted B4> Inventory (BSO Lakewood and Golden) found that the <Redacted B4> does not contain examples of all critical defects, including: "Improper crimp (not gripping the lip of the vial)" and "Stopper on vial crooked or compromised".
This <Redacted B4> is intended to serve as the reference library of vials from which the <Redacted B4> are createa to assess the proficiency of visual inspectors. The absence of representative examples of all critical container-closure integrity defects prevents adequate demonstration that personnel can consistently identify defects which pose a risk to product sterility.
Liquid Injectable products include Testosterone Cypionate/Anastrozole 200mg/0.5 mg; Testosterone Cypionate/ Anastrozole 200mg/1mg; Testosterone Cypionate/DHEA 200mg/I0mg.
REPEAT OBSERVATION
Observation 3
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
AMENDMENT 1
Specifically,
Your firm's procedure, SOP 12, Visual Inspection of Pellets (BSO-Lakewood & Golden), Version 26, Effective 03/19/2025, is deficient in that it does not contain several critical elements necessary to ensure the consistent detection and classification of defects in sterile pellet products:
a. The SOP does not classify defects into Critical, Major, and Minor categories. Instead, defects are categorized only as container-closure, physical, or packaging defects, without linkage to severity.
b. The procedure does not include definitions of Critical, Major, and Minor defect categories, preventing consistent interpretation by personnel conducting inspections.
c. The SOP does not establish acceptance criteria linked to defect severity. ...
Observation 4
The written stability program does not assure testing of the drug product in the same container-closure system as that in which the drug product is marketed.
Specifically,
AMENDMENT 1
Your firm has not conducted stability studies in the packaging system currently used for distribution to demonstrate that assigned expiration date is appropriate for the following products. Without container-specific stability data, there is no assurance that product quality is maintained for the duration of the labeled shelf life. Your firm was unable to provide data to support the <Redacted B4> expiry period for the products listed below in their current clear vials container-closure system:
a. Anastrozole ( 6 mg) pellets
b. Estradiol (6 mg, 10 mg, 12.5 mg, 15 mg, 18 mg, 20 mg, 25 mg, 37.5 mg, 50 mg) pellets
C. Progesterone (50 mg, 75 mg) pellets
Observation 5
The written stability program for drug products does not include specific test methods.
Specifically,
Drug products are not tested for critical quality attributes to ensure they maintain their identity, strength, quality, and purity throughout the expiry period.
a. Lack of Photostability Studies for drug products stored in clear containers that may be light sensitive: Your firm manufactures the following light-sensitive products, and are packaged & and released in clear, non-light-resistant containers. Your stability studies oor 1.VP/PQ003. l .VR and BSO.SS.008.lP-RT.TC_A_DHEALiquidlnjectables <Redacted B4> Summary) do not contain any data to demonstrate that the packaging protects the drug from photodegradation. No photostability studies have been performed on the drug product in its container-closure system to demonstrate its protection from light. Failure to demonstrate photostability increases the risk of degradation and reduced potency or altered safety profile during distribution and storage.
• Estradiol (6 mg, 10 mg, 12.5 mg, 15 mg, 18 mg, 20 mg, 25 mg, 37.5 mg, 50 mg) pellets
AMENDMENT 1 ...
Observation 6
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically,
a. Lack of Dissolution testing: Your firm does not perform dissolution testing to evaluate the drug release characteristics of the following products. Without dissolution testing, there is no assurance that these products will release the active ingredient at the intended rate and extent, which may result in sub-therapeutic dosing or drug toxicity.
• Anastrozole ( 6 mg) pellets
• Estradiol (6 mg, 10 mg, 12.5 mg, 15 mg, 18 mg, 20 mg, 25 mg, 37.5 mg, 50 mg) pellets
• Progesterone (50 mg, 75 mg) pellets
• Testosterone (12.5 mg, 25 mg, 37.5 mg, 50 mg, 62.5 mg, 70 mg, 80 mg, 87.5 mg, 100 mg, 200 mg BLNT) pellets
• Testosterone/< 2 % Cholesterol (100 mg, 200mg, 200 mg BLNT) pellets
• Testosterone/< 4 % Cholesterol (12.5 mg, 25 mg, 37.5 mg, 50 mg, 62.5 mg, 70 mg, 80 mg, 87.5 mg, 100 mg, 200 mg, 200 mg BLNT) pellet
b. Lack of Impurities and Degradation testing: Your firm does not conduct testing for impurities and degradants in the following products prior to release. ...
Observation 7
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
Specifically,
a. Your firm's procedure SOP 35, <Redacted B4> sterilization Testing Samples and Finished Drug Test Samples and Retains (BSO-Lakewood, & Golden), Version 13.0, Effective 04/30/2025, does not provide instructions for the annual visual examination of reserve samples (pellets and liquid injectable products). There is no defined requirement or trigger for initiating investigations or recall assessments if critical defects are identified during the review of reserve samples.
b. SOP 35 does not require review of retained samples as part of complaint investigations for sterile pellet products, including when critical defects are reported. This omission may prevent the firm from identifying systemic quality issues related to manufacturing, packaging, or handling. Nor is this process included in SOP 12, Visual Inspection of Pellets (BSO-Lakewood & Golden), Version 26, Effective 03/19/2025. ...
Observation 8
AM ENDMENT 1
Aseptic processing areas are deficient in that floors and walls are not smooth and/or hard surfaces that are easily cleanable.
Specifically,
a. On 07/09/2025, I observed multiple locations of hard-to-clean wall and floor surfaces in ISO-8 Cleanroom 1, the Inspection Room, and the Pellet Press Room. There are numerous locations of peeling paint and holes on the walls exposing drywall and crumbling drywall along the seam of the air return vent, Chipped sections on the air vent return screen, and several locations on the floor marked with red tape that exhibited residue or powder buildup. These conditions were observed while the following operations were occurring:
• Pellet Pressing, Cleanroom 1-Estradiol 6 mg Lot # <Redacted B4> • Vial and Capping -Cleanroom I Inspection Room, Estradiol 12.5 mg <Redacted B4> • 100% Pellet Weighing, Cleanroom I Inspection Room, Estradiol 6 mg <Redacted B4> • 100% Pellet Weighing, Cleanroom I Inspection Room, Estradiol 25 mg <Redacted B4> \
b. ...
Observation 9
AMENDMENT 1
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Specifically,
The vacuum oven used in the production of Estradiol, Testosterone, Testosterone/Cholesterol ~2%, and Testosterone/Cholesterol ~4% <Redacted B4> has not been qualified for its current operating temperature range.
e oven is qualified for Operation at <Redacted B4>; however, your firm is routinely operating the oven at <Redacted B4> during the <Redacted B4> drying process. There is no documented qualification or performance data to demonstrate that the oven maintains uniform and controlled conditions at this higher temperature range.
Th
Inspection Jun 25, 2024 to Jul 3, 2024: 5 observations
- Firm on the cover
- BSO LLC, 1 2860 W Cedar Dr Ste 211, Lakewood, CO 80228-1971
- FEI number
- 3011976853
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6 th & Kip ling St. (P.O. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation ofthe sterilization process.
Specifically,
a. Your firms sterilization validation studies used to sterilize pellets produced by your facility are inadequate. Your firm was unable to produce evidence of the material used to perform dose mapping. Dose mapping with material of <Redacted B4> is used to determine the minimum and maximum dose areas within a product container, thereby establishing a loading pattern to ensure the sterilization process is reproducible. Evidence provided states "Pellets in Bottles". Since the material is unidentified, it is unclear if the material used has the same attenuation and scattering properties similar to those ofthe product, material, or substance to be <Redacted B4> thus establishing that products of all densities received enough <Redacted B4>, to render them sterile. ...
Observation 2
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
Specifically,
a. Your firm's Visual Inspection Program is inadequate. Section 6.3.2 of SOP 27, Visual Inspection for Liquid lnjectables, Version 5.0, Effective Date 09/22/2023, defines Critical Defect as a defect that <Redacted B4>. Your firm maintains <Redacted B4> that is used for the qualification of personnel to perform visual inspection. They 'M<f does not contain any examples of critical defects currently identified such as broken or cracked glass, particulate matter (glass particles), improper crimp (not gripping lip of vial), incorrect color or clarity. Your firm does not have documented evidence that the visual inspectors can identify critical defects of liquid injectable products produced in your facility. The <Redacted B4> does not contain examples of all Major Defects identified in Table 1, section 7.1 of WI 27-01, Liquid lnjectables Visual Inspection Procedures, Version 2.0, Effective Date 09/22/2023. Missing Major defects include Broken Caps, and Under-crimped caps. ...
Observation 3
Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
Specifically,
Your firm failed to establish a hold times between start of batch manufacturing and <Redacted B4> sterilization for Anastrozole 10 mg (for example Lot <Redacted B4> Expiration Date: 05/08/2025) and Anastrozole 20 mg (for exampl:~Lot <Redacted B4> Expiration Date: 05/08/2025). Both lots of Anastrozole were held for a period of <Redacted B4> prior to sterilization.
Observation 4
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
You have not conducted investigations to identify the source of particulates identified as major defects during the initial 100% Visual Inspection ofyour liquid injectable products.
Sec 6.3.3.3 ofSOP 27, Version 5.0, Effective Date 09/22/2023, states <Redacted B4> "Section 6.4. 6. The Quality Manager will detennine ifan investigation, deviation, or assessment is warranted.
For example, Testosterone Cypionate/DHEA 200mg /10 mg/ ml (Lot <Redacted B4> Expiration Date: 10/15/2024), rejected 95 vials for Major defect (Particle in solution: Black, white, or any color fiber, etc.). No investigation was opened to determine the source of the particle. Testosterone Cypionate /Anastrozole 200mg / 1 mg/ ml (Lot <Redacted B4> Expiration Date: 10/15/2024), rejected 99 vials for Major defect (Particle in solution: Black, white, or any color fiber, etc.). No investigation was opened to determine the source of the particle. ...
Observation 5
The written stability testing program is not followed.
Specifically,
Your firm lacks stability data to support the 360-day BUD for Anastrozole 10 mg and 20 mg doses. Your firm currently distributes Anastrozole 6 mg, 10 mg, and 20 mg pellets.
Inspection Mar 1, 2021 to Mar 11, 2021: 4 observations
- Firm on the cover
- BSO LLC, 12860 W Cedar Dr Ste 211, Lakewood, CO 80228-1971
- FEI number
- 3011976853
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
For example:
Non Conformance Investigation INV20018 covered EM excursions on 7/14/20 and 7/28/20. Excursions occurring 7/14/20 and 7/28/20 at the gowning room computer area (Clean Room <Redacted B4> ISO 8, where compounded drugs, such as Testosterone monitoring excursion exceeding the action limit <Redacted B4> Pellets, are made) concerned surface viable cfu). Counts were 30 and 32 cfu respectively. Viable air limits were also exceeded on 7/14/20 in the area by the hanging gowns at TNTC (too numerous to count); the action limit is <Redacted B4> cfu. Various organisms were found in the surface and air monitoring samples indicating origins from human skin Q %), with plants, soil and water accounting for <Redacted B4> % of results. Root cause was determined to be failure to follow procedures, but what actually was the cause specifically lacked thorough investigation. No documented data supported the conclusion that procedures weren't followed. ...
Observation 2
Procedures for the cleaning and maintenance of equipment are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembling equipment as necessary to assure proper cleaning and maintenance.
For example:
a) Manual cleaning procedures for (shared) drug processing equipment do not always include details such as precise parameters, e.g., time required for cleaning, equipment used and volume of cleaning solvent to be utilized. Technician subjectivity, not actual delivery of cleaning process parameters, sometimes determines whether equipment is adequately cleaned in a process where cleaning validation was performed. Reproducible and consistent results are therefore not assured. ...
Observation 3
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A).
Per 503B(a)(1 0)(B)(i), if there is not space on the product label for information described under subparagraph (A)(iii)(X), this information should be included on the container label.
Specifically, the following information is not found on your drug product label or container label:
a) A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Examples of your drug product labels that do not contain this information:
Examples of your drng product labels that do not contain this info1mation:
• Testosterone 100 mg Pellet
Observation 4
You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2).
Specifically, you compound drug products that are not identical or nearly identical to an approved drug, but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.
Examples of compounded drug products that are essentially a copy of one or more approved drugs include:
• Testosterone 50 mg Pellet
• Testosterone 80 mg Pellet
• Testosterone 100 mg Pellet
• Estradiol 10 mg Pellet
• Estradiol 20 mg Pellet
• Progesterone 50 mg Pellet
• Anastrozole 6 mg Pellet
Inspection Sep 9, 2019 to Sep 20, 2019: 2 observations
- Firm on the cover
- BSO LLC DBA Belmar Select Outsourcing, 12860 W Cedar Dr Ste 211, Lakewood, co 80228-1971
- FEI number
- 3011976853
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087 ) Denver, co 80225-008 7
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Equipment and utensils are not cleaned at appropriate inte1vals to prevent contamination that would alter the safety, identity, strength, quality or pmity of the diug product.
Specifically, validation/verification of the cleaning methods for tools and equipment used in the manufacture of pellet diug products has not been proven. Data examined for the cleaning from testosterone/cholesterol pellets and from progesterone pellets have inappropriate acceptance c1i te1ia.
Observation 2
Procedmes designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
LJ A.) An employee in the blending/granulation room (ISO 8) of cleanroom <Redacted B4> was observed on 09/09/2019 with a beard cover that did not completely cover the beard.
B.) On the same day, an umbrella was observed inverted on a plastic tray. Both the umbrella and tray were located in an unclassified area reserved for temporary storage of quarantine non-ingredient materials such as caps and vials.
State board of pharmacy records
No license with this exact name and city was found in the Colorado State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: Discipline the Department of Regulatory Agencies publishes with each license in the dataset (case number, program action and effective date), worded as the department gives it. Actions in the data are dated Oct 11, 1985 to Oct 30, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NSF 127 | Nonresident Outsourcing Facility | Bso Llc Dba Belmar Select Outsourcing | Lakewood, CO | Active |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0010082 | Outsourcing Facility-Distributor | BSO LLC (dba Belmar Select Outsourcing) | LAKEWOOD, CO | Active |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301011574 | Pharmacy | Belmar Select Outsourcing | Lakewood, CO | Active |
FDA’s 503B list
- BSO LLC, Lakewood, CO: last inspection Jul 16, 2025, Form 483 at that inspection: Yes, action FDA lists: Regulatory Meeting Held 3/3/2026.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.